Analysis Of Racial Disparities Research Articles

Abstract 4136636: Analysis of Racial Disparities in the Training Path to Cardiology: Trends from 2012 to 2022

Introduction: Substantial evidence indicates that racial and ethnic diversity among the physician workforce bridges cultural gaps and improves patient care. Trends in racial diversity across the full training pipeline from undergraduate to practicing cardiologist are not yet well-characterized. Aims: We analyze racial disparities at each stage of training towards becoming a practicing cardiologist, and identify changes in these disparities between 2012 and 2022. Methods: We conducted a retrospective analysis of data specifying the racial composition of medical trainees acquired from the Association of American Medical Colleges, Accreditation Council for Graduate Medical Education, and Electronic Residency Application Service. Population data was acquired from the US Census Bureau. We computed the representation quotient (RQ) for each racial group at each stage to compare representation among the trainees or physicians to age-matched segments of the US population. Results: RQ decreases from undergraduate to active cardiologist for African Americans (0.719 to 0.314), Hispanics (0.660 to 0.359), American Indians (0.551 to 0.221), and Native Hawaiians (1.121 to 0.512). The lowest RQs of 0.133 and 0.137 were observed for American Indian active internal medicine residents and cardiology fellows, respectively. Racial disparities in medical education declined between 2012 and 2022, with RQs increasing from 0.541 to 0.735 for African American medical school matriculants and from 0.444 to 0.578 for Hispanic medical school matriculants. Similar increases were seen in the active cardiologist population for African Americans (2013 RQ: 0.227, 2022 RQ: 0.342) and Hispanics (2013 RQ: 0.283, 2022 RQ: 0.375). Conclusion: While racial diversity in the cardiology training pipeline has increased over the last decade, significant disparities persist for under-represented minorities. Addressing these barriers will help achieve a cardiology workforce reflective of the diverse population it serves.

The prognosis and treatment of newly diagnosed bone metastasis of head and neck squamous cell cancer: an analysis of racial disparity.

There is a lack of research investigating racial disparity in newly diagnosed head and neck squamous cell carcinoma with isolated bone metastases (HNSCC-BM). This study aims to investigate the clinical characteristics and prognostic factors in HNSCC-BM patients from different racial backgrounds to aid clinical decision making and management. We retrieved data from the Surveillance, Epidemiology, and End Results (SEER) database for 345 cases of HNSCC-BM that were diagnosed between 2010 and 2017. Survival was compared using univariate and multivariate Cox proportional hazards models, Kaplan-Meier analysis, and log-rank tests. We also used propensity score matching to adjust for confounders. In white patients, those who were over 40years of age had a significantly shorter survival (HR, 4.49; 95% CI 1.03-19.56; P < 0.05). Female black patients were found to survive longer compared to male patients (HR, 0.34; 95% CI 0.15-0.76; P < 0.01). Single (never married) Asians had shorter survival than married Asians (HR, 4.68; 95% CI 1.34-16.41; P < 0.05). In all three racial groups, patients who received radiotherapy in addition to chemotherapy did not survive longer than those receiving chemotherapy (P > 0.05). In Asian patients, those who underwent surgery at the primary site combined with chemoradiotherapy had significantly better survival outcomes than those who received chemoradiotherapy (HR: 0.10, 95% CI 0.01-0.88; P = 0.01). Prognostic factors differ between HNSCC-BM patients from different racial backgrounds.

Analysis of Racial Disparity among U.S. Patients with Gynecologic Cancers and COVID-19 Infection

Gynecologic cancer care has been affected by the COVID-19 pandemic. We studied the association of racial disparity and COVID infection in the care of patients with gynecologic cancers. To assess the association of racial disparity and COVID infection in gynecologic cancers the National Cancer Database (NCDB) was queried for the year 2020 for patients with histologically confirmed diagnosis of cervical, endometrial and ovarian cancers. Patients were divided into two cohorts based on COVID test result status and subsequently stratified based on race. Race/ethnicity was categorized as 1) non-Hispanic White (NHW), 2) non-Hispanic Black (NHB), and 3) Hispanic. Subjects with missing race/ethnicity information were excluded. Outcome variables were time from diagnosis to initiation of treatment (surgery, radiation therapy versus chemotherapy). Continuous and categorical variables were reported as median [interquartile range] and number [rate] and were compared using Mann-Whitney U test and Chi-Square test, respectively. Statistical software was used and the level of significance was set at 0.05. A total of 36,863 subjects with newly diagnosed gynecologic cancers in 2020 underwent had available COVID testing information (4,827 with cervical, 23,935 with endometrial, and 8,101 with ovarian cancer). 31,516 (85.5%), 4,735 (12.8%), and 612 (1.7%) of the population were NHW, NHB, and Hispanic, respectively. The overall rate of COVID infection was the highest in NHB (6.9%), followed by Hispanic (5.6%) and NHW (5.4%), p < 0.001. Patients with cervical cancer had the highest rate of COVID infection (7.3%), followed by ovarian (5.6%) and endometrial (5.2%), p < 0.001. Non-Hispanic Black women with cervical cancer had the highest rate of infection (8.6%). Median time from diagnosis to first surgical procedure was highest in COVID positive NHB subjects (52 [IQR 20-91] in NHB, 41 [IQR 12-67] in NHW, and 40 [IQR 9-58] in Hispanics, p = 0.02). Median time from diagnosis to first radiation treatment was also highest in COVID positive NHB subjects (83 [IQR 29-107] in NHB, 52 [IQR 17-67] in NHW, and 39 [IQR 9-51] in Hispanics, p = 0.04). There was not racial or ethnic disparity in time from diagnosis to the first systemic therapy. COVID pandemic has substantially impacted gynecologic cancer care in the United States and exacerbated existing healthcare disparities. Members of African American community with gynecologic cancers have been affected the most compared to other racial groups, both in terms of COVID infection rates and delays in receiving care. Further study is warranted to understand impact on long-term cancer related outcomes.

Abstract 1945: Racial disparities in comprehensive cancer tumor profiling testing from real-world data of 100,000 cancer patient records

Abstract Inequities in cancer patient outcomes and healthcare utilization by race and ethnicity are coming to the forefront. Overcoming these inequities requires a better understanding of the extent of such disparities across cancer types and medical interventions. Here, we studied the race and ethnicity of patients receiving tumor profiling for therapy decision support by examining real-world data (RWD) from 100,000 de-identified patient records across major cancer types. Tumors and normal tissue (when available) were sequenced with the Tempus xT assay, a 648-gene next-generation sequencing panel. Since race and ethnicity metadata are frequently incomplete in RWD, we imputed these categories from continental genetic ancestry inferred from genotypes of 654 ancestry informative markers obtained from sequencing data. Using a heuristic that combines East Asian, African, Amerindian, European, and South Asian ancestry proportions, we imputed Asian (A), Non-Hispanic Black (NHB), Hispanic/Latino/Native American (HIS), and Non-Hispanic White (NHW) categories with &amp;lt;2% error rate (based on available metadata), leaving 3% of unclassified patients due to complex admixture. NHW patients are overrepresented in the cohort at 72% as compared to NHB (11%), HIS (9%) and ASN (5%). We compared the distributions of patients by race/ethnicity categories across specific cancer types against the overall cohort race/ethnicity distributions. These distributions were compared to the expected distribution under the null hypothesis of no relationship by the χ2 test of independence. Significantly (p&amp;lt;0.05) over/under-represented categories in each cancer type were compared to ranks of incidence by race/ethnicities in SEER program data at the national level. Differences are of a smaller magnitude in NHW as compared to the other races/ethnicities. We observed several differences that are concordant with SEER; for example, overrepresentations of NHB in breast, colorectal, and endometrial cancers, which correspond to high incidences of these cancers for NHB. Notably, we observed several discordances with SEER incidence rate ranks, including underrepresentation of NHB in pancreatic and urinary tract cancers, underrepresentation of NHW in breast and colorectal cancers, overrepresentation of ASN in gallbladder and biliary cancer, and overrepresentation of HIS in colorectal cancer. These differences can be the result of a complex interplay of factors, such as stage of the disease at sequencing, access to early-stage curative therapies, comorbidities/cofactors, access to care, insurance, socioeconomic status, and others. Nonetheless, our results show that analysis of racial disparities can be performed with RWD, and this information can be useful in studying causes and devising strategies to improve healthcare equity. Citation Format: Francisco M. De La Vega, Brooke Rhead, Yannick Pouliot, Justin Guinney. Racial disparities in comprehensive cancer tumor profiling testing from real-world data of 100,000 cancer patient records [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1945.

National Trends in Complications of Vascular Access for Hemodialysis and Analysis of Racial Disparities Among Patients With End-Stage Renal Disease in the Inpatient Setting

The aim of this study is to assess the trends in access-related complications, as well as the impact of race on these complications, among admitted patients with end-stage kidney disease (ESKD) receiving hemodialysis. A retrospective cohort study between 2005 and 2018 was performed using the National Inpatient Sample (NIS). Hospitalizations involving ESKD and hemodialysis were identified. There were 9,246,553 total admissions involving ESKD and hemodialysis, of which 1,167,886 (12.6%) had complications. Trends in complications were assessed and compared among races. There was a decreasing trend in rates of mechanical (trend:-0.05% per year; P< 0.001), inflammatory or infectious (-0.48%; P< 0.001), and other (-0.19%; P< 0.001) complications from 2005 to 2018. Non-White patients had a greater magnitude in the decrease in trends in rates of complications compared to White patients (-0.69% per year vs.-0.57%; P< 0.001). Compared to the White patients, Black patients (odds ratio [OR]: 1.26; P< 0.001) and those of the other races (OR: 1.11; P< 0.001) had higher odds of complications. These differences were also statistically significant among lower socioeconomic classes (75 percentile vs. 0-25 percentile: P= 0.009) and within southern states (vs. Northeast: P< 0.001). Although there was an overall decrease in the trends of dialysis-associated complications requiring hospitalization among ESKD patients receiving hemodialysis, non-White patients have higher odds of complications compared to White patients. The findings in this study emphasize the need for more equitable care for hemodialysis patients.

Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality.

Compared with conventional external-beam radiation therapy (cEBRT) for patients with breast cancer (BC) and prostate cancer (PC), shorter radiation regimens may be associated with lower treatment noncompletion rates. We assess disparities in receipt of shorter radiation regimens and treatment noncompletion for BC and PC. The 2004-2017 National Cancer Database was queried for adjuvant cEBRT or hypofractionated EBRT (hEBRT) for nonmetastatic BC; and definitive cEBRT, moderate hypofractionation (mEBRT), or stereotactic body radiotherapy (SBRT) for localized PC. Multivariable logistic regression identified factors associated with treatment noncompletion and receipt of shorter regimens. We identified 170,386 men with PC (median age [interquartile range], 70 [64-75] years; Black, 17.5%; White, 82.5%) and 306,846 women with BC (61 [52-69] years; Black, 12.3%; White, 87.7%). Among patients who received cEBRT for PC, Black men had higher treatment noncompletion rates compared with White (14.1% v 13.0%; odds ratio [95% CI] 1.07 [1.03 to 1.12]; P < .001). In contrast, treatment noncompletion was not disparate with SBRT (Black 1.6% v White 1.3%; 1.20 [0.72 to 2.00], P = .49) or mEBRT (Black 9.0% v White 7.1%; 1.05 [0.72 to 1.54], P = .79). From 2004 to 2017, SBRT (0.07% to 11.8%; 1.32 [1.31 to 1.33]) and mEBRT (0.35% to 9.1%; 1.27 [1.25 to 1.28]) increased (both P < .001); however, Black men were consistently less likely to receive SBRT (7.4% v White, 8.3%; 0.84 [0.79 to 0.89], P < .001). Among women with BC, there were no racial differences in treatment noncompletion; however, hEBRT was associated with lower treatment noncompletion rates (1.0% v cEBRT 2.3%; 0.39 [0.35 to 0.44], P < .001). Although hEBRT for BC increased (0.8% to 35.6%) between 2004 and 2017, Black women were less likely to receive hEBRT (10.4% v 15.3%; 0.78 [0.75 to 0.81], P < .001). Black patients were consistently less likely to receive hypofractionated radiation for PC or BC, despite evidence suggesting that shorter regimens may lower rates of treatment noncompletion with similar oncologic outcomes.

Abstract No. 523 National trends in complications of vascular access for hemodialysis and analysis of racial disparities among patients with end-stage renal disease

Abstract No. 523 National trends in complications of vascular access for hemodialysis and analysis of racial disparities among patients with end-stage renal disease

Abstract P3-14-14: A mediation analysis of racial disparity in breast cancer survival

Abstract Introduction: Non-Hispanic Black (African American, AA) women have the worst breast cancer outcomes of any racial/ethnic group. In comparison to non-Hispanic white (white) women, disparities in breast cancer survival for AA women have persisted over the past several decades, although there has been some recent improvement both at the national level and for AA women in Florida. However, we recently reported that AA women in Florida still have twice the rate of breast cancer death compared to their white counterparts. Therefore, more targeted approaches are needed to eliminate survival disparities for AA women diagnosed with breast cancer. The purpose of this study was to conduct a multiple mediation analysis to identify the most important factors causing the disparity in breast cancer survival for AA women. Identifying the most important mediators will provide opportunities for targeted policies, programs, and interventions to ultimately eliminate the prognostic effect of race/ethnicity for Florida women diagnosed with breast cancer. Methods: The study population is comprised of women in Florida diagnosed with breast cancer between 2004 and 2015 who were reported to the Florida Cancer Data System. The following putative mediators were analyzed in this study: residence in high poverty neighborhoods, having Medicaid or no insurance, advanced disease stage at diagnosis, high tumor grade, negative hormone receptor status, and receipt of surgery, based on our causal diagram. The outcome of interest was 5-year breast cancer-specific death. Sociodemographic and clinical characteristics were compared between African American and white women. The Cox model was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the direct effect of AA race/ethnicity and indirect effects via mediators. Age was treated as a confounder in the model and mediators were treated as independent. The relative effect for African American ethnicity and each mediator, which is the percentage of the total effect of AA race/ethnicity explained (directly and indirectly) on breast cancer survival, are also provided. Results: African American women were more likely to be younger at diagnosis, living in high poverty neighborhoods, to be insured via Medicaid or uninsured, to have more advanced disease (stage, grade) with hormone receptor negative tumors, and less likely to receive surgery as treatment. From our mediation model, after accounting for all potential mediators, the direct effect associated with African American ethnicity was a 17% (HR = 1.17: 95% CI, 1.11-1.23) increased rate of breast cancer death, which represented 3.9% of the total racial/ethnic effect. The indirect and relative effects of mediators are provided in Table 1. Conclusions: This analysis identified receipt of surgery, advanced disease stage, hormone receptor negative disease, insurance status, and high tumor grade as the most important mediators of the racial/ethnic disparity in breast cancer survival for African American women in Florida. These results have ramifications for increasing access to screening services, providing options for health insurance, and ensuring prompt receipt of curative surgery to eliminate the prognostic effect of race/ethnicity for African American women diagnosed with breast cancer in the Florida. Study limitations are that these results are hypothesis generating based on the current status of methodology to examine multiple mediators in survival models. Table 1.Direct and Indirect Effects for the Association of African American Race/Ethnicity with 5-year Breast Cancer-Specific SurvivalDirect &amp; indirect effectsCox Proportional Hazard ModelHR95%. CIrel effAA race/ethnicity (Direct Effect)1.171.11, 1.233.9%Surgery3.182.93, 3.4728.3%Advanced stage3.092.84, 3.3627.5%Hormone receptor negative1.581.51, 1.6511.1%Medicaid-Uninsured1.481.40, 1.579.6%High grade1.471.42, 1.539.4%High poverty1.341.23, 1.477.2%Hormone treatment1.111.09, 1.142.5%Immunotherapy1.081.02, 1.151.9%Radiation1.041.03, 1.051.0%Chemotherapy0.910.89, 0.92Total Effect60.1050.8, 71.1100.0%Abbreviations: AA, African American; HR, hazard ratio; CI, confidence interval. Citation Format: Robert B. Hines, Xiang Zhu, Eunkyung Lee, Carolyn Rapp, Albert Volk, Asal M. Johnson. A mediation analysis of racial disparity in breast cancer survival [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-14-14.

Analysis of racial disparities in time to treatment initiation and survival among patients with advanced cancers.

127 Background: Racial disparities in cancer care have received increased attention in recent years. One previously identified disparity is in the time to treatment initiation (TTI) – a factor closely associated with outcomes. While most research in the US to date has focused on the Medicaid and Medicare populations, this study examined disparities between different racial/ethnic groups in TTI and overall survival (OS) among patients with cancer managed in the community setting. Methods: Using the Flatiron Health electronic health record database, patients diagnosed with advanced non-small cell lung cancer (aNSCLC), metastatic colorectal cancer (mCRC), metastatic breast cancer (mBC), multiple myeloma (MM), advanced gastroesophageal cancer (aGastric), advanced urothelial cancer (aUL), metastatic renal cell carcinoma (mRCC) or advanced melanoma (aMel) and treated with first-line (1L) therapy, with ≥1 month of follow-up during 2014-2019, were included. Patient characteristics, TTI and outcomes were compared across race/ethnicity groups classified as White, Black, Asian and Hispanic/Latino/Other (Other). Results: A total of 81,543 patients were evaluated (37% aNSCLC, 19% mCRC, 15% mBC, 8% MM, 6% aGastric, 5.2% aUL, 5.0% mRCC and 4.1% aMel); 67% were White, 9% Black, 3% Asian and 11% Other. Overall, TTI was similar across race/ethnicity groups (median range 1.1–1.2 months), and 44% of all patients received treatment ≤30 days post-diagnosis. Overall Survival (months). Median OS varied by tumor and race/ethnicity groups (Table). However, multivariate Cox proportional hazards analysis showed that Asian patients had better OS than Black patients in many cancers (hazard ratio [HR] 0.8 aNSCLC, 0.75 mBC, 0.63 aGastric, 0.59 aUL, 0.81 mCRC, 0.68 mRCC), while White patients had better survival than Black patients in mBC (HR 0.8) and aGastric (HR 0.87). Conclusions: In this real-word analysis, TTI did not differ by race/ethnicity group for any of the cancers examined. However, some differences in OS emerged on multivariate analysis – this was longer in Asian than Black patients in aNSCLC, mBC, mCRC, aGastric, aUL and mRCC, and longer in White than Black patients in mBC and aGastric. Given the small sample size in some groups, further analyses are needed to determine the influence of race/ethnicity on cancer care and outcomes.[Table: see text]

Analysis of racial disparities in acute type A aortic dissection repair at a rural tertiary academic medical center.

To determine if racial disparities exist between African Americans (AA) and Non-Hispanic Whites (NHW) for patients undergoing repair of acute type A aortic dissection (ATAAD) at a rural tertiary academic medical center. There were 215 consecutive AA and NHW patients who underwent ATAAD repair at our institution from 1999 to 2019 included in a retrospective analysis of our Society of Thoracic Surgeons Adult Cardiac Surgery Database. Statistical analysis was performed with a p value of less than .05 considered statistically significant. Patients undergoing ATAAD repair were 47% AA despite comprising only 27% of the total population in our region. AAs were significantly younger (54.0 vs. 61.2 years), were more likely to be hypertensive (94.1% vs. 79.7%), had higher creatinine levels (1.7 vs. 1.1 mg/dL), and higher body mass index (30.8 vs. 28.1 kg/m2 ) (all p values < .006). There were no significant differences in type of repair or intraoperative variables. A logistic regression analysis showed AAs had an increased rate of postoperative acute renal failure not requiring hemodialysis when compared to NHWs (20.8% vs. 10.6%, p value = .042). Thirty-day mortality was not significantly different (15.7% vs. 13.4%) nor was 1-year survival (78% vs. 79%) in AAs and NHWs, respectively. Despite AAs having more medical comorbidities at presentation, there were no differences in short- and intermediate-term survival. In our catchment of 1.8 million people, AAs appear to undergo ATAAD repair at a disproportionate rate versus NHWs. These findings may alter strategies for surveillance and prevention of aortic disease in this high-risk population.

Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000-2016

In the US, dementia risk is higher in non-Hispanic Black individuals than in non-Hispanic White individuals. To evaluate progress toward reducing such disparities, tracking secular trends in racial disparities in dementia prevalence is essential. To examine whether relative racial disparities in dementia prevalence or incidence have changed in the US from 2000 to 2016. The Health and Retirement Study (HRS) is a nationally representative study of adults 50 years or older. New participants are recruited every 6 years, and study visits occur biennially. Approximately 17 000 to 22 000 respondents have been surveyed at each wave since 2000, achieving response rates of 81% to 89%. Data for this cohort study were obtained from non-Hispanic White and non-Hispanic Black participants aged 70 years and older from the 2000 to 2016 waves. For analyses of secular trends in racial disparities in dementia prevalence, each HRS wave was considered separately (range of participants meeting eligibility criteria in each wave, 6322-7579). For analyses of secular trends in racial disparities in dementia incidence, 7 subcohorts were created (range of participants meeting eligibility criteria in each subcohort, 5322-5961) following up people without dementia for 4 years from subcohort baseline visits in 2000, 2002, 2004, 2006, 2008, 2010, and 2012. Data were analyzed from October 2019 to August 2020. Race based on self-response to closed-ended survey questions. Dementia status was determined using 3 algorithms with similar sensitivity and specificity across non-Hispanic White and Black participants. Disparities were characterized using ratio measures. In this study, the mean age and percentage of male participants eligible for inclusion in analyses of racial disparities in dementia prevalence increased over time among non-Hispanic White participants (from 78.2 years and 40% in 2000 to 78.7 years and 44% in 2016) but remained steady in non-Hispanic Black participants during the same period (from 78.0 years and 37% in 2000 to 77.9 years and 38% in 2016). Prevalence ratios comparing Black and White participants ranged from approximately 1.5 to 1.9 across algorithms and years, whereas hazard ratios ranged from approximately 1.4 to 1.8. Although results suggest stable or declining dementia risk overall, there was no evidence suggesting change in relative racial disparities in dementia prevalence or incidence during follow-up. This study did not find evidence to suggest that the ratio of dementia risk across Black and White individuals changed in the US between 2000 and 2016. Additional efforts to identify and mitigate the source of these disparities is warranted.

Analysis of Racial Disparities in Overall Survival and Disease Recurrence in Patients with Breast Cancer Diagnosed at Age 35 or Younger

Analysis of Racial Disparities in Overall Survival and Disease Recurrence in Patients with Breast Cancer Diagnosed at Age 35 or Younger

Racial Disparities in Outcomes of Reconstructive Breast Surgery: An Analysis of 51,362 Patients from the ACS-NSQIP.

In various surgical specialties, racial disparities in postoperative complications are widely reported. It is assumed that the effect of race can also be found in plastic surgical outcomes, although this remains largely undefined in literature. This study aims to provide data on the impact of race on outcomes of reconstructive breast surgery. Data were collected using the NSQIP (National Surgical Quality Improvement Program) database (2008-2016). Outcomes of the reconstructive breast surgery of White patients were compared with those of African American, Asian, or other races. Logistic regression was performed to control for variations between all groups. Analysis of racial disparities was further sub-stratified according to four different types of breast reconstruction: delayed or immediate autologous, and delayed or immediate prosthesis-based reconstruction. In total, this study included 51,362 patients of which 43,864 were Caucasian, 5,135 African American, 2,057 Asian, and 332 of other races. When compared with White patients, patients of African American race had larger body mass indices (31.3 ± 7.0 vs. 27.6 ± 6.3, p-value < 0.001) in addition to higher rates of diabetes (12.3 vs 4.6%, p-value < 0.001) and hypertension (44.7 vs. 23.4%, p-value < 0.001). Both multivariate analysis and the sub-stratified analysis of different types of reconstruction showed no differences in overall complication rate. Among the four types of reconstructive procedures, differences in surgical outcomes do not appear to be based on race and therefore seem to be less evident in reconstructive breast surgery compared with the current literature within other surgical specialties.

Abstract C005: Racial disparity, stage at diagnosis, and treatment patterns of colorectal cancer: Analysis of data from a hospital-based cancer registry, Virginia 2008-2016

Abstract Background: Using hospital-based cancer registry data, we examined the predictors of late-stage CRC diagnosis and identified factors contributing to CRC treatment patterns in Virginia. Methods: We conducted a retrospective cohort study using the Sentara Cancer Registry for patients diagnosed with CRC from 2008 to 2016. Patients' demographics and clinical characteristics were summarized and compared between Caucasian and African American in a bivariate analysis using the Chi-square test for categorical variables, and the Student's t test for continuous variables. A hierarchical logistic regression model adjusting for age, sex, race, marital status, primary payer, cancer site, initial year of diagnosis, and the Charlson Comorbidity Index (CCI) was used to model the odds of late-stage CRC disease, and to determine factors associated with treatment patterns, i.e., surgery, chemotherapy, and radiation. Adjusted odds ratios with their 95% confidence intervals were reported. Results: The data consisted of 4,505 cases of CRC reported to Sentara hospitals during 2008 to 2016. Among these patients, 2,371 (54.34%) were diagnosed late and 1,992 (45.66%) were early-stage diagnosis. About three quarters of the patients were Caucasian (74.93%). On average, patients were 65.95 years old (SD=13.22), and the majority were males (52.01%), married (55.8%), and had primarily Medicare (57.02%), followed by private insurance (31.88%). During the study period, the overall rate of CRC diagnosis decreased from 12.32% in 2008 to 10.36% in 2016. About 47.26% of the patients had a Charlson Comorbidity Index (CCI) score ≤ 2. The bivariate analysis of racial disparity revealed that African American with CRC are younger than their counterpart Caucasian (p &amp;lt; 0.0001), and they are generally more likely to be late-stage diagnosis (59.41% vs. 52.65%; P &amp;lt; 0.0001). Time to treatment initiation is statistically higher among Black than White (p = 0.0307). The fully adjusted multilevel logistic regression model showed a nonexistent racial disparity in late stage diagnosis between White and Black. The odds of late-stage CRC diagnosis were higher among younger patients (&amp;lt;50), those with a CCI score greater than 5, and among the uninsured and self-pay (All P&amp;lt;0.05). For treatment patterns, younger patients (&amp;lt;50) had higher odds of having surgery, performing chemotherapy and radiation. The odds of surgery are less likely among Black and more likely among those with a private insurance, and a CCI score between 3 and 5 (All P&amp;lt;0.05). Finally, the likelihood of performing radiation is statistically significantly less among patients with a CCI score between 3 and 5 and above 5, [OR=0.563 (95%CI: 0.398 - 0.795]. Race, sex, and marital status were not significant predictors of late stage CRC, chemotherapy, and radiation. Conclusion: The impact of patient demographics and clinical factors on late stage and treatment patterns is striking in Virginia. These findings suggest the need for policy to try to delineate those factors associated with those disparities. Citation Format: Hadiza Galadima, Georges Adunlin, Marybeth Hughes, and Jennifer May. Racial disparity, stage at diagnosis, and treatment patterns of colorectal cancer: Analysis of data from a hospital-based cancer registry, Virginia 2008-2016 [abstract]. In: Proceedings of the Eleventh AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2018 Nov 2-5; New Orleans, LA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl):Abstract nr C005.

Racial disparities in the outcomes of transitional cell carcinoma of the bladder: A population-based analysis.

577 Background: Bladder cancer is the most common type of genitourinary malignancy and is the fourth most common cancer in men in the US. Transitional cell carcinoma (TCC) of the bladder accounts for most bladder cancer cases. Previous studies have observed racial disparities in the prognosis between white and black populations with very little mentioned about other ethnicities and race groups that are part of the United States population. We hereby, present a detailed and comprehensive analysis of racial disparities in TCC survival in the US. Methods: Using the data from surveillance Epidemiology and End results (SEER) database, we identified patients with TCC between 1992 and 2015. We used multivariable covariate-adjusted Cox models to analyze the overall and TCC-specific survival of patients according to their race. Results: We evaluated 176,388 patients with TCC and after we adjusted for age, sex, race, stage, grade, and undergoing cancer-targeted surgery, we found that Asians/Pacific Islanders and Hispanics had a better overall survival when compared to whites (HR= 0.792, 95% CI [0.761-0.824], P&lt;.001 and HR = 0.941, 95% CI [0.909-0.974], P = .001, respectively). Asians/Pacific Islanders also showed better TCC specific survival (HR = 0.843, 95% CI [0.759-0.894], P&lt;.001). Blacks had worse overall survival and TCC-specific survival (HR =1.221, 95% CI [1.181-1.262], P &lt;.001 and HR =1.325, 95% CI [1.268- 1.384], P &lt;.001, respectively). When stage IV TCC was analyzed separately, only Hispanics showed better overall and TCC specific survival when compared to whites (HR = 0.896, 95% CI [0.806-0.997], P = 0.044 and HR = 0.891, 95% CI [0.797-0.996], P = 0.42). Conclusions: Asians/Pacific Islanders have better overall and TCC-specific outcome while blacks have the worst outcome compared to whites. Hispanics have better overall and cancer specific survival in stage IV TCC. These disparities likely related to different and complex factors from lifestyle and chemical exposure to genetic factors. Further studies can help us more in understanding and approaching this malignancy in different race groups.

Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults

BackgroundThe incidence of colorectal cancer (CRC) in young adults is increasing. Minority populations with CRC are known to have worse survival outcomes. The aim of this study is to evaluate adults under age 50 years with CRC by race and ethnicity. MethodsData were obtained from all US hospitals that contributed to the National Cancer Database (NCDB) between 2004 and 2013. Univariate and multivariable testing was done to identify factors associated with patient outcome. Kaplan-Meier analysis and Cox proportional hazards models were used for association between patient characteristics and survival. ResultsA total of 83,449 patients between 18 and 50 years of age were identified. Median age was 45 years (SD ± 6), with male preponderance (53.9%). 72% were non-Hispanic Whites (NHW), Blacks (AA) were 15.1% and Hispanics (who did not identify as Blacks) were 8.3% of the study population. Distribution across stages IIV was 15.6%, 22.4%, 33.9% and 27% consecutively. 41.8% of NHW and 28.4% of AA had rectal cancers (p < 0.001). Despite equally receiving standard of care (SOC) as per national guidelines, AA had significantly lower 5-year survival rates (58.8%) compared to Hispanics (64.8%) and NHW (66.9%; HR 1.42; 1.38-1.46; p < 0.001). Furthermore, NHW (HR 0.85; 0.81-0.88; p < 0.001) and Hispanics (HR 0.75; 0.70-0.79; p < 0.001) were more likely to benefit from chemotherapy compared to AA. SOC utilization was associated with improved survival across all racial groups, especially in AA (HR 0.64; 0.60-0.69; p < 0.001). ConclusionDespite comparable rates of SOC utilization, AA young adults had worse survival outcomes compared to other races. More colon (compared to rectal) cancers in AA may have contributed to their worse outcomes.

Police discretion, organizational characteristics, and traffic stops: An analysis of racial disparity in illinois

An important source of racial disparity in policing is traffic enforcement. The level of discretion afforded to officers for traffic enforcement is generally greater than it is for other policing decisions. One way to control misuse of discretion is through minority representation, which is the extent that the racial composition of the police agency matches that of the local community. Using data from the Illinois Department of Transportation (IDOT) and the 2013 Law Enforcement Management and Administrative Statistics (LEMAS), this study examines how social context and police organizational variables (e.g., minority representation) relate to enforcement outcomes. We find that organizational measures, including minority representation, relate to written citations and consent search requests. Moreover, non-white population size conditions the effect of minority representation on traffic stops and citations. These results highlight the importance of accounting for both social context and organizational characteristics when research examines discretionary police behavior.

Resolution of apparent paradoxes in the race-specific frequency of use-of-force by police

Analyses of racial disparities in police use-of-force against unarmed individuals are central to public policy interventions; however, recent studies have come to apparently paradoxical findings concerning the existence and form of such disparities. Although anti-black racial disparities in U.S. police shootings have been consistently documented at the population level, new work has suggested that racial disparities in encounter-conditional use of lethal force by police are reversed relative to expectations, with police being more likely to: (1) shoot white relative to black individuals, and (2) use non-lethal as opposed to lethal force on black relative to white individuals. Encounter- and use-of-force-conditional results, however, can be misleading if the rates with which police encounter and use non-lethal force vary across officers and depend on suspect race. We find that all currently described empirical patterns in the structuring of police use-of-force—including the “reversed” racial disparities in encounter-conditional use of lethal force—are explainable under a generative model in which there are consistent and systemic biases against black individuals. If even a small subset of police more frequently encounter and use non-lethal force against black individuals than white individuals, then analyses of pooled encounter-conditional data can fail to correctly detect racial disparities in the use of lethal force. In more technical terms, statistical assessments of racial disparities conditioned on problematic intermediate variables, such as encounters, which might themselves be a causal outcome of racial bias, can produce misleading inferences. Population-level measures of use-of-force by police are more robust indicators of the overall severity of racial disparities than encounter-conditional measures—since the later neglect the differential morbidity and mortality arising from differential encounter rates. As such, population-level measures should be used when evaluating the local-level public health implications of racial disparities in police use-of-force. Research on encounter-conditional use-of-force by police can also fruitfully contribute to public policy discussions, since population-level measures alone cannot address whether racial disparities are driven by disparities in encounters or disparities in use-of-force conditional on encounters. Tests for racial biases in the encounter-conditional use of lethal force, however, must account for individual-level variation across officers in terms of race-specific encounter rates or risk falling to Simpson’s paradox.

Abstract P4-10-13: Analyses of racial disparities in genetic testing and surgical management of patients with triple-negative breast cancer in the era of multigene panel testing

Abstract Background Under-utilization of genetic counseling and testing among African-American (AA) women with breast cancer (BC) has been reported in previous studies, and there are concerns that disparities may widen with further genomic advances. Our objective was to compare AA and Caucasian (CC) patients with triple-negative breast cancer (TNBC) with regards to referral for genetic counseling, patterns of genetic testing, and patient-compliance with genetic counseling recommendations. We chose TNBC since a majority of these patients would qualify for genetic counseling ± testing. We also analyzed for differences between the two races in prevalence of deleterious BC-associated mutations, stage of BC on presentation, and surgical choices. Methods In this retrospective medical records-based observational study, we included all patients in our tumor registry with TNBC diagnosed between 09/01/2013 and 02/28/2017. Race, clinical characteristics and details pertaining to genetic counseling and testing were recorded. X2 test was used to compare categorical variables. A p-value &amp;lt; 0.05 was considered significant. Results 477 patients -358 CC and 96 AA- with TNBC were included. Mean age was 60.3 years. 331 patients met National Comprehensive Cancer Network (NCCN) criteria for genetic counseling - of these, 85.5% had genetic consult order placed, 72.8% attended counseling, and 71.9% underwent genetic testing (multigene panel testing 55.0%, BRCA 1/2 testing 39.9%, single-site testing 2.5%, and multisite-3 testing 2.5%). Between CC and AA, no significant differences were found in the proportion of qualifying patients who had referral for genetic counseling (84.7 vs 87.7%, p=0.562), attended counseling (72.2% vs 73.7%, p=0.816), or underwent genetic testing (72.1% vs 70.1%, p=0.764). The choices of type of genetic tests were also not significantly different between the two groups (p=0.349). Though the prevalence of highly penetrant mutations in breast cancer-associated genes trended to be higher among CC than AA (14.1% vs 9.5%), this difference did not reach statistical significance (p=0.429). In our population, stage of TNBC at presentation was comparable between the two races – 80.4% of CC presented with stage I or II disease compared to 80.2% of AA (p=0.931). The two groups were also comparable with regards to the choices of breast surgery and reconstruction, as shown in the table. CaucasiansAfrican-Americansp-valueSurgery TypePartial Mastectomy154(47.4%)38(44.7%)0.317 Unilateral Mastectomy101(31.1%)35(41.2%) Bilateral Mastectomy70(21.5%)12(14.1%)ReconstructionYes96(56.1%)24(51.1%)0.535 No75(43.9%)23(48.9%)Reconstruction TypeImplant87(90.6%)19(79.2%)0.118 Tissue Flap9(9.4%)5(20.8%) Conclusions Contrary to previous reports, in this cohort of TNBC patients, we did not identify significant disparities between AA and CC in patterns of referral for genetic counseling, in patient compliance with testing or in type of testing performed. Also, no significant differences were found between the two races in choices of breast surgery or reconstruction. As a caveat, with an overall insured rate of ˜97% across our network, the uninsured population may have been under-represented by our cohort. Citation Format: Gopalakrishnan D, Yanda C, Abbas H, Kline M, Stephens M, Grobmyer SR, Pederson HJ. Analyses of racial disparities in genetic testing and surgical management of patients with triple-negative breast cancer in the era of multigene panel testing [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-10-13.

Abstract B44: Adjusted American Joint Committee on Cancer 6th edition stage for analysis of trends in black-white disparities in non-small cell lung cancer, SEER Medicare, 2000-2011

Abstract Purpose: Analyses of racial disparities in survival and treatment trends may be confounded by changes over time in cancer staging systems. For Surveillance, Epidemiology, and End Results (SEER) data linked with Medicare claims, non-small cell lung cancer (NSCLC) is available with American Joint Committee on Cancer (AJCC) 3rd edition stage from 2000–2003, and with AJCC 6th edition (AJCC6) stage from 2004–2011. We wanted to maximize the number of years that AJCC6 stage was available for analysis of trends. In this study, we describe the results of our methods to assign all NSCLC cases from 2000–2011 with stage group equivalent to AJCC6, and our assessment of black-white differences by stage and year following the stage reclassification. Methods: We focused on SEER-Medicare linked NSCLS cases, diagnosed 2000–2011, enrolled in Medicare during the month of diagnosis, and with SEER race coded as white or black. We used SEER Extent of Disease 1988 (10 digit) codes to assign AJCC6 to cases diagnosed 2000–2003, Collaborative Stage version 1 to assign AJCC6 to cases diagnosed 2004–2009, and Collaborative Stage version 2 to assign AJCC6 to cases diagnosed 2010–2011. To evaluate our adjusted AJCC6, we calculated the percentage point (pp) differences in the proportions of cases by stage and race between 2003 and 2004, and also for the 2000–2003, 2004–2009, and 2010–2011 sub-cohorts. In addition, we used SEER Joinpoint regression analysis to calculate annual percentage change (APC) by stage and race, including coincident and parallel pairwise comparisons by race. We defined statistical significance as p&amp;lt;0.05. Results: Our final study cohort included 156,125 white and 16,594 black NSCLC cases. Overall from 2000 to 2011, the proportion of cases by stage was: IA (12.4%), IB (11.8%), IIA (1.2%), IIB (4.5%), IIIA (9.9%), IIIB (18.0%), and IV (41.0%); the remaining 1.2% were categorized Occult Carcinoma or Stage 0. The mean difference in proportions for stages I to IV between 2003 and 2004 was 0.3 pp, but the difference by specific stage varied up to 4.1 pp. The proportion Stage IA was higher in whites than in blacks (3.1 pp in 2000–2003; 3.7 pp in 2004–2009; and 3.5 pp in 2010–2011). The proportion Stage IV was higher in blacks than in whites (2.6 pp in 2000–2003; 3.2 pp in 2004–2009; and 3.5 pp in 2010–2011). Differences in proportions between whites and blacks for Stage IIA, IIB, and Stage IIIA were less than 1 pp for each of the three time periods. Proportions by stage for whites were greater than those for blacks for Stage IA to Stage IIB, and proportions by stage for blacks exceeded those for whites for Stage IIIB and Stage IV. The predicted proportions of white and black cases diagnosed at Stage IIIA were statistically identical. Significant changes in APCs were present among whites in Stage IA (at 2004), Stage IB (at 2006 and 2009), and Stage IV (at 2004). No statistically significant changes in APCs were detected among blacks. Conclusion: Our methods to reclassify NSCLC cases according to AJCC6 appear reasonable to support analyses that require cancer stage and race of all cohort patients diagnosed between 2000 and 2011. Some year-to-year differences are present, but they appear at most 4.1 pp between 2003 and 2004. Following the stage reclassification, our results suggest that whites were more likely to be diagnosed at a favorable stage (IA, IB, IIA, and IIB) compared with blacks, while blacks were more likely to be diagnosed at a less favorable stage (IIIB and IV) compared with whites. Citation Format: Thomas B. Richards, Serban Negoita, Timothy S. McNeel, Dylan L. Holt, Marie Topor, S Jane Henley, Arica White, Jun Li, Chunyu Li. Adjusted American Joint Committee on Cancer 6th edition stage for analysis of trends in black-white disparities in non-small cell lung cancer, SEER Medicare, 2000-2011. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr B44.